Novo Nordisk — GLP-1 Dominance Is Real, But the Entry Point Isn't Here

18 Jun 2026 · NVO live score → · HOLD

Novo Nordisk is the company behind Ozempic and Wegovy, the GLP-1 drugs that have redefined obesity treatment and reshaped healthcare spending globally. The addressable market — obesity affects 40% of the US adult population — is enormous, and Novo's first-mover advantage with semaglutide is substantial.

The business is executing well. Ozempic and Wegovy revenues grew 74% year-over-year in 2025 and are on pace for a similar trajectory in 2026. Manufacturing capacity has been the binding constraint — Novo has invested 5B in production expansion since 2023 and is now beginning to clear the backlog. Once supply meets demand, the revenue ceiling comes off.

However. The stock has already priced much of this. NVO is trading at 40x forward earnings, which requires continued execution without any clinical setbacks or competitive erosion. Eli Lilly's tirzepatide (Mounjaro/Zepbound) is taking market share in the US. Rybelsus, the oral version, is proving that the delivery mechanism matters. The next-generation oral GLP-1s from multiple competitors will be the real test of Novo's durability.

The technical picture supports patience. NVO is 18% above its 200-day moving average and RSI has been running above 65 for six consecutive weeks. The entry score is in the low 50s — not a setup where the risk/reward is favorable. Extended from both trend and momentum measures.

If you don't own it, wait. The business is exceptional but the stock needs to come in 15-20% before the entry score gets into buy territory. Let it breathe. Good companies come back to their averages — that's the entry.

Scores in this piece come from the ZonedInOut model. How the score works →

Get the Sunday Brief

One email a week, before the open: what the board did, which calls worked, which didn't, and what changed. Free. No spam, unsubscribe anytime.